I just bought shares of Intra-Cellular Therapies because J&J is acquiring them at a significant premium. The potential for Caplyta's sales growth and ...
Read
More
I just bought shares of Intra-Cellular Therapies because J&J is acquiring them at a significant premium. The potential for Caplyta's sales growth and the acquisition itself signal strong upside for ITCI in the coming months.